London Co. of Virginia Buys 36,670 Shares of Enovis Co. (NYSE:ENOV)

London Co. of Virginia increased its stake in shares of Enovis Co. (NYSE:ENOV - Free Report) by 8.5% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 468,799 shares of the company's stock after purchasing an additional 36,670 shares during the period. London Co. of Virginia owned approximately 0.82% of Enovis worth $20,571,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ENOV. UMB Bank n.a. increased its stake in shares of Enovis by 128.2% in the fourth quarter. UMB Bank n.a. now owns 778 shares of the company's stock worth $34,000 after purchasing an additional 437 shares in the last quarter. Envestnet Portfolio Solutions Inc. raised its holdings in Enovis by 19.5% during the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 15,433 shares of the company's stock valued at $677,000 after acquiring an additional 2,518 shares during the period. Assenagon Asset Management S.A. bought a new stake in Enovis during the fourth quarter valued at about $437,000. Tributary Capital Management LLC boosted its stake in shares of Enovis by 33.9% in the fourth quarter. Tributary Capital Management LLC now owns 566,089 shares of the company's stock worth $24,840,000 after acquiring an additional 143,258 shares during the period. Finally, Park Avenue Securities LLC grew its position in shares of Enovis by 12.5% during the fourth quarter. Park Avenue Securities LLC now owns 11,988 shares of the company's stock worth $526,000 after purchasing an additional 1,333 shares in the last quarter. Hedge funds and other institutional investors own 98.45% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on ENOV shares. JMP Securities dropped their target price on shares of Enovis from $62.00 to $55.00 and set a "market outperform" rating for the company in a research report on Friday, May 9th. Canaccord Genuity Group cut their price objective on Enovis from $75.00 to $70.00 and set a "buy" rating for the company in a research report on Wednesday. Finally, Needham & Company LLC decreased their target price on Enovis from $64.00 to $57.00 and set a "buy" rating on the stock in a research report on Friday, May 9th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $58.00.

Enovis Price Performance

Shares of Enovis stock traded up $0.37 during trading hours on Friday, reaching $36.10. The company's stock had a trading volume of 539,929 shares, compared to its average volume of 777,333. The stock has a market cap of $2.06 billion, a P/E ratio of -16.49 and a beta of 1.79. Enovis Co. has a one year low of $29.32 and a one year high of $53.31. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.27 and a quick ratio of 1.12. The firm has a 50 day moving average price of $35.16 and a 200-day moving average price of $41.45.

Enovis (NYSE:ENOV - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported $0.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.07. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. The firm had revenue of $558.83 million during the quarter, compared to analyst estimates of $558.80 million. During the same quarter last year, the business earned $0.50 EPS. The business's revenue was up 8.2% on a year-over-year basis. On average, analysts predict that Enovis Co. will post 2.79 EPS for the current year.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.